1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Job or no Job?

Discussion in 'Kimberly-Clark' started by Anonymous, May 16, 2014 at 2:06 PM.

  1. Anonymous

    Anonymous Guest

    U guts work for KC....seriously. U r one step about in home health care reps. 2 steps above used car salesmen. Hang on as long as u can. My friend works with u guys and he's asked many times before to get in with a top company...sorry. U'd have to be 400% to quota for 8 years to be qualified...the fact is u are all making 65-140k. And your all over paid by 20-100k.
     
  2. Anonymous

    Anonymous Guest

    who the hell is Price?
    I've been here 7 years and I have never heard of him. And he is going to save this company?
     
  3. Anonymous

    Anonymous Guest

    Price is not his real name. His real name is John Galt. Who is John Galt?
     
  4. Anonymous

    Anonymous Guest

    He's the sausage king of Chicago. please get with the program newbie.